---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-003872"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T01:44:42.435498+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MaxCyte FY2022 total revenue $44.3M (+31% YoY); net loss $23.6M

## Summary
- Q4 2022 revenue $12.4M (+22% YoY); core revenue $10.6M (+4%); gross margin 88%.
- Full-year core business revenue $39.6M, up 26%; cell therapy segment grew 33%.
- Net loss $23.6M vs $19.1M; EBITDA loss $24.8M; cash and equivalents $227.3M.
- 18 active SPL partnerships; potential pre-commercial milestones >$1.55B.
- 2023 guidance: total revenue growth 21-26%, core growth 20-25%, SPL program revenue ~$6M.

## SEC filing metadata
- accession: 0001558370-23-003872
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837023003872/0001558370-23-003872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837023003872/mxct-20230315x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-003872
- JSON: https://secwatch.observer/filing/0001558370-23-003872.json
- Plain text: https://secwatch.observer/filing/0001558370-23-003872.txt

## Key facts
- Earnings Releases
  MAXCYTE, INC. updated its the quarter and year ended December 31, 2022 guidance (initiated).
  - Period: the quarter and year ended December 31, 2022
  - Guidance: initiated
  - Result: reported results
  source text: On March 15, 2023, MaxCyte, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. This press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837023003872/0001558370-23-003872-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.